Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are... see more

Recent & Breaking News (NDAQ:ALDX)

Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Business Wire September 16, 2020

Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

Business Wire September 10, 2020

Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients

Business Wire September 9, 2020

Aldeyra to Participate in Citi's 15th Annual BioPharma Virtual Conference

Business Wire September 3, 2020

Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update

Business Wire August 6, 2020

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Business Wire August 4, 2020

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update

Business Wire July 30, 2020

Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners

Business Wire July 14, 2020

Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020

Business Wire July 13, 2020

Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease

Business Wire July 7, 2020

Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program

Business Wire June 15, 2020

Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease

Business Wire June 4, 2020

Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Business Wire June 3, 2020

Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting

Business Wire May 20, 2020

Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update

Business Wire May 19, 2020

Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs

Business Wire May 7, 2020

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update

Business Wire April 30, 2020

Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629

Business Wire April 14, 2020

Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection

Business Wire March 24, 2020

Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

Business Wire March 12, 2020